Melanomas represent only 4% of all skin cancers, but their mortality rate is more than 50% of
any other skin cancer. Alteration in genetic and environmental factors are the risk factors for …

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling
pathway. About 50% of melanomas harbors activating BRAF mutations (over 90% V600E) …

Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …

Melanoma is an aggressive form of skin cancer that causes the greatest number of skin
cancer-related deaths worldwide. In its early stages malignant melanoma can be cured by …

Introduction: The clinical activity of BRAF inhibitor (BRAF-I) therapy is a major breakthrough
in the treatment of metastatic melanoma carrying BRAF mutations. However, the therapeutic …

ABSTRACT Introduction: Approximately, 30.4–66.0% of cutaneous melanomas possess a
mutation in the BRAF gene that activates downstream signaling through the mitogen …

Small molecule inhibitors of BRAF in clinical trials - ScienceDirect Skip to main contentSkip to
article Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue …

According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors
are among the most promising chemotherapy regimens for the treatment of advanced BRAF …

Activating mutations in the BRAF gene are among the most prevalent kinase mutations in
human cancer. BRAF mutations are most frequent in patients with melanoma where they …

The identification and pharmacological targeting of activating BRAF mutations in melanoma
has led to significant improvements in patient outcomes. This perspective paper illustrates …